Kurt J. Hilzinger - Sep 29, 2022 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Director
Signature
/s/ Lawrence A. Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Sep 29, 2022
Transactions value $
$110,500
Form type
4
Date filed
10/3/2022, 05:19 PM
Previous filing
Jul 5, 2022
Next filing
Oct 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OTLK Common Stock Purchase $16.4K +13.8K +5.05% $1.19 287K Sep 29, 2022 Direct F1
transaction OTLK Common Stock Purchase $41.8K +33.2K +11.57% $1.26 320K Sep 30, 2022 Direct F2
transaction OTLK Common Stock Purchase $52.2K +41.8K +13.06% $1.25 362K Oct 3, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 - $1.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.19 - $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 - $1.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.